Evolocumab
- TRADE NAME: Repatha (Amgen)
- INDICATIONS: Heterozygous or homozygous familial hypercholesterolemia where additional lowering of low density lipoprotein cholesterol is required; hyperlipidemia
- CLASS: Monoclonal antibody, Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
- HALF-LIFE: 11–17 days
FDA APPROVAL DATE: 08/27/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
No data available but likely to cross the placenta in second and third trimester
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of evolocumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric